



PPD Celebrates 25 Years with Ringing of Nasdaq Opening Bell

Continues to build upon strong history of scientific expertise and innovation

WILMINGTON, N.C. (June 29, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it will [ring the Nasdaq Stock Market Opening Bell](#) on July 1 at 9:30 a.m. ET to commemorate PPD's history as one of the world's leading contract research organizations.

"For the past 25 years, we have built a solid foundation based on delivering scientific expertise, quality service and innovative technologies to help our clients deliver safe, effective medicines to patients," said Fred Eshelman, executive chairman of PPD. "We take great pride in what we have achieved for our clients and shareholders and will continue to adapt to the changing drug discovery and development landscape as we plan for PPD's long-term growth and success."

The ceremony will highlight the company's accomplishments in growing from a one-person consulting firm to one of the world's largest contract research organizations. Today, PPD has more than 10,500 employees with offices in 41 countries.

"We have a strong history and legacy of assisting clients in achieving their research and development goals," said David Grange, chief executive officer of PPD. "Our employees across the globe bring passion and dedication to advancing drug development."

PPD completed its initial public offering and began trading on the Nasdaq National Market System in 1996. The company was included in the Nasdaq Global Select Market in 2006.

The event will be shown on Nasdaq's MarketSite tower in New York City's Times Square and through a live video feed at <http://investor.ppidi.com/events.cfm>.

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 41 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppidi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD's 25th anniversary and future growth prospects, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: success in sales growth; competition within the outsourcing industry; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; loss of large contracts; increased cancellation rates; the ability to attract and retain key personnel; rapid technological advances that make our services less competitive; risks associated with and dependence on collaborative relationships; risks associated with acquisitions and investments, such as integration and impairments; risks that we may not continue our dividend policy; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media:

Sue Ann Pentecost

+1 919 456 5890

sueann.pentecost@ppdi.com

Analysts/Investors:

Luke Heagle

+1 910 558 7585

luke.heagle@ppdi.com